OSE IMMUNOTHERAPEUTICS financials
OSE IMMUNOTHERAPEUTICS
969500HIUWVGY6NZSM05 | Line item | 2025 | 2024 |
|---|---|---|
| Income statement | ||
| Operating profit (EBIT) | -€37.5M | €43.7M |
| Net finance income / (cost) | €72.0K | -€3.9M |
| Finance costs | €2.9M | €5.6M |
| Profit before tax | -€37.4M | €39.8M |
| Income tax expense | €275.0K | €2.4M |
| Profit for the year | -€37.7M | €37.4M |
| Total comprehensive income | -€37.7M | €37.4M |
| Per share | ||
| Basic EPS | €-1.69 | €1.71 |
| Diluted EPS | €-1.69 | €1.46 |
| Free cash flow / share | €-1.53 | €1.89 |
| Cash flow statement | ||
| Net cash from operating activities | -€34.0M | €48.4M |
| Net cash from investing activities | €41.4M | -€46.9M |
| Net cash from financing activities | -€6.5M | -€3.5M |
| Proceeds from borrowings | €790.0K | €2.1M |
| Repayments of borrowings | €7.2M | €5.4M |
| Lease liability payments | €735.0K | €810.0K |
| Balance sheet | ||
| Total assets | €78.9M | €124.0M |
| Non-current assets | €46.9M | €54.0M |
| Property, plant & equipment | €311.0K | €355.0K |
| Right-of-use assets | €3.4M | €3.1M |
| Current assets | €32.0M | €69.9M |
| Trade & other receivables | €311.0K | €4.1M |
| Cash & equivalents | €17.6M | €16.7M |
| Total equity | €27.8M | €63.8M |
| Non-current liabilities | €26.2M | €39.9M |
| Long-term borrowings | €21.8M | €35.7M |
| Lease liabilities (non-current) | €2.8M | €2.7M |
| Current liabilities | €24.9M | €20.2M |
| Lease liabilities (current) | €768.0K | €595.0K |
| Deferred tax liabilities | €1.2M | €1.1M |
| Derived metrics | ||
| Free cash flow | -€34.1M | €48.4M |
| Operating margin | -1431.3% | 62.6% |
| Net margin | -1439.1% | 53.6% |
| Return on equity | -135.8% | 58.7% |
| Cash conversion ratio | 0.90× | 1.29× |
| Capex coverage | -347.29× | 629.09× |
| Other reported items | ||
| Adjustments For Decrease Increase In Other Current Assets | -€2.3M | €4.1M |
| Adjustments For Decrease Increase In Other Operating Receivables | -€4.4M | €0 |
| Adjustments For Decrease Increase In Trade Account Receivable | €3.8M | -€3.2M |
| Adjustments For Finance Costs | -€72.0K | €3.9M |
| Adjustments For Income Tax Expense | €275.0K | €2.4M |
| Adjustments For Increase Decrease In Employee Benefit Liabilities | -€76.0K | -€53.0K |
| Adjustments For Increase Decrease In Other Liabilities | -€857.0K | €1.8M |
| Adjustments For Increase Decrease In Trade Account Payable | €1.1M | -€1.6M |
| Adjustments For Losses Gains On Disposal of Noncurrent Assets | €100.0K | €0 |
| Adjustments For Provisions | €938.0K | €0 |
| Adjustments For Sharebased Payments | €1.5M | €2.1M |
| Cash Flows From Used In Operations Before Changes In Working Capital | -€36.2M | €49.1M |
| Current Borrowings and Current Portion of Noncurrent Borrowings | €10.0M | €7.2M |
| Current Financial Assets | €14.1M | €49.0M |
| Current Payables On Social Security and Taxes Other Than Income Tax | €3.2M | €2.7M |
| Current Provisions | €918.0K | €0 |
| Deferred Tax Assets | €193.0K | €191.0K |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | €0 | €0 |
| Equity and Liabilities | €78.9M | €124.0M |
| Expense From Sharebased Payment Transactions With Employees | €1.9M | €2.7M |
| Finance Income | €3.0M | €1.7M |
| General and Administrative Expense | €8.8M | €6.5M |
| Income Tax Relating To Components of Other Comprehensive Income | -€4.0K | €4.0K |
| Income Taxes Paid Refund Classified As Operating Activities | €0 | €0 |
| Increase Decrease In Cash and Cash Equivalents | €809.0K | -€1.9M |
| Increase Decrease Through Sharebased Payment Transactions | €1.5M | €2.1M |
| Increase Decrease Through Treasury Share Transactions | €72.0K | €167.0K |
| Intangible Assets Other Than Goodwill | €41.5M | €44.0M |
| Interest Paid Classified As Financing Activities | -€554.0K | €469.0K |
| Issued Capital | €4.5M | €4.4M |
| Noncurrent Financial Assets | €1.5M | €6.4M |
| Noncurrent Provisions | €348.0K | €415.0K |
| Other Comprehensive Income | -€7.0K | -€20.0K |
| Other Comprehensive Income Before Tax Exchange Differences On Translation | -€7.0K | €15.0K |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | €4.0K | -€39.0K |
| Other Comprehensive Income Net of Tax Exchange Differences On Translation | €1.0K | -€35.0K |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | -€7.0K | €15.0K |
| Other Inflows Outflows of Cash Classified As Financing Activities | €0 | €0 |
| Other Operating Income Expense | €4.4M | €0 |
| Other Revenue | €72.0K | €13.6M |
| Proceeds From Issuing Shares | €71.0K | €1.2M |
| Purchase of Property Plant and Equipment Intangible Assets Other Than Goodwill Investment Property and Other Noncurrent Assets | €98.0K | €77.0K |
| Rent Deferred Income Classified As Noncurrent | €0 | €100.0K |
| Research and Development Expense | €33.9M | €30.4M |
| Retained Earnings Profit Loss For Reporting Period | -€37.7M | €37.4M |
| Revenue From Contracts With Customers | €2.6M | €69.9M |
| Share Premium | €77.7M | €77.7M |
| Trade and Other Current Payables To Trade Suppliers | €8.8M | €7.7M |
| Treasury Shares | €338.0K | €448.0K |
| Weighted Average Shares | 22.3M | 21.8M |
Every line item above is a fact tagged in OSE IMMUNOTHERAPEUTICS's annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (EUR), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.